NO20052108L - Terapeutiske peptider. - Google Patents

Terapeutiske peptider.

Info

Publication number
NO20052108L
NO20052108L NO20052108A NO20052108A NO20052108L NO 20052108 L NO20052108 L NO 20052108L NO 20052108 A NO20052108 A NO 20052108A NO 20052108 A NO20052108 A NO 20052108A NO 20052108 L NO20052108 L NO 20052108L
Authority
NO
Norway
Prior art keywords
ligand
present
provides
therapeutic peptides
product
Prior art date
Application number
NO20052108A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052108D0 (no
Inventor
Mumtaz Virji
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of NO20052108D0 publication Critical patent/NO20052108D0/no
Publication of NO20052108L publication Critical patent/NO20052108L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
NO20052108A 2002-10-02 2005-04-29 Terapeutiske peptider. NO20052108L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222764.3A GB0222764D0 (en) 2002-10-02 2002-10-02 Therapeutic peptide
PCT/GB2003/004273 WO2004031236A2 (en) 2002-10-02 2003-10-01 Therapeutic uspa1-derived peptides

Publications (2)

Publication Number Publication Date
NO20052108D0 NO20052108D0 (no) 2005-04-29
NO20052108L true NO20052108L (no) 2005-06-27

Family

ID=9945111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052108A NO20052108L (no) 2002-10-02 2005-04-29 Terapeutiske peptider.

Country Status (17)

Country Link
EP (2) EP2305700A1 (de)
JP (1) JP4763291B2 (de)
KR (1) KR101057587B1 (de)
CN (1) CN1305899C (de)
AT (1) ATE549348T1 (de)
AU (1) AU2003299131B2 (de)
BR (1) BR0315031A (de)
CA (1) CA2500960A1 (de)
ES (1) ES2383958T3 (de)
GB (1) GB0222764D0 (de)
IL (1) IL167780A (de)
MX (1) MXPA05003474A (de)
NO (1) NO20052108L (de)
NZ (1) NZ539575A (de)
PL (1) PL376052A1 (de)
WO (1) WO2004031236A2 (de)
ZA (1) ZA200503446B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735446A2 (de) * 2004-04-15 2006-12-27 University Of Bristol Therapeutische peptide
EA014352B1 (ru) 2005-08-10 2010-10-29 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948625B1 (de) * 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Moraxella catarrhalis antigene uspa1 und uspa2

Also Published As

Publication number Publication date
HK1076475A1 (en) 2006-01-20
CN1705678A (zh) 2005-12-07
CN1305899C (zh) 2007-03-21
ATE549348T1 (de) 2012-03-15
EP2305700A1 (de) 2011-04-06
AU2003299131B2 (en) 2010-04-22
IL167780A (en) 2011-05-31
AU2003299131A1 (en) 2004-04-23
EP1546194A2 (de) 2005-06-29
NZ539575A (en) 2006-06-30
KR101057587B1 (ko) 2011-08-19
WO2004031236A2 (en) 2004-04-15
BR0315031A (pt) 2005-08-16
ES2383958T3 (es) 2012-06-27
PL376052A1 (en) 2005-12-12
MXPA05003474A (es) 2005-10-18
JP2006516952A (ja) 2006-07-13
CA2500960A1 (en) 2004-04-15
GB0222764D0 (en) 2002-11-06
JP4763291B2 (ja) 2011-08-31
ZA200503446B (en) 2006-10-25
EP1546194B1 (de) 2012-03-14
KR20050067410A (ko) 2005-07-01
WO2004031236A3 (en) 2004-06-24
NO20052108D0 (no) 2005-04-29

Similar Documents

Publication Publication Date Title
Boardman et al. Essential role of the response regulator Rrp2 in the infectious cycle of Borrelia burgdorferi
Zivcec et al. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus
McMurry et al. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes
Maeda et al. Adjuvant-mediated epitope specificity and enhanced neutralizing activity of antibodies targeting dengue virus envelope protein
Karamloo et al. Prevention of allergy by a recombinant multi‐allergen vaccine with reduced IgE binding and preserved T cell epitopes
Choi et al. Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice
Scholzen et al. Promiscuous Coxiella burnetii CD4 epitope clusters associated with human recall responses are candidates for a novel T-cell targeted multi-epitope Q fever vaccine
Tanaka et al. Micrurus snake species: venom immunogenicity, antiserum cross-reactivity and neutralization potential
Rangel-Santos et al. Immunosuppresive role of principal toxin (crotoxin) of Crotalus durissus terrificus venom
CA3232870A1 (en) Coronavirus vaccines and methods of use
CN101575361B (zh) 新型特异性多肽及其在制备诊断和防治冠状病毒引起的严重急性呼吸综合征药物中的应用
Davis et al. Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans
NO20052108L (no) Terapeutiske peptider.
WO1998029444A1 (en) Broad spectrum pyrogenic exotoxins antagonists and vaccines
NO20065201L (no) terapeutiske peptider
Shimizu et al. Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells
Crowe et al. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity
Rajnavölgyi et al. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites
WO2013173910A1 (en) A novel toxin in type a clostridium perfringens
WO2022131832A1 (ko) 신규 코로나바이러스 예방 및 치료용 백신 조성물
CA2901333C (en) Novel toxins in type a clostridium perfringens
Mori et al. Two novel Salp15‐like immunosuppressant genes from salivary glands of Ixodes persulcatus Schulze tick
AU2003279352B2 (en) DNA sequence and recombinant production of the grass pollen allergen Phl p4
Lim et al. Autoreactive responses to an environmental factor. 2. Phthalate‐induced anti‐DNA specificity is downregulated by autoreactive cytotoxic T cells
Karras et al. Human thyroglobulin peptide p2340 induces autoimmune thyroiditis in HLA-DR3 transgenic mice

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application